These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30905200)

  • 1. Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.
    Matos I; Noguerido A; Ros J; Mulet N; Argilés G; Elez É; Tabernero J
    Expert Opin Investig Drugs; 2019 May; 28(5):463-471. PubMed ID: 30905200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.
    Wang L; Chen X; Li W; Sheng Z
    Anticancer Drugs; 2012 Feb; 23(2):155-60. PubMed ID: 21955998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
    Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
    Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
    Moehler M; Thomaidis T; Zeifri C; Barhoom T; Marquardt J; Ploch P; Schattenberg J; Maderer A; Schimanski CC; Weinmann A; Woerns MA; Kranich AL; Warnecke JM; Galle PR
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):515-22. PubMed ID: 25230900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance strategy in metastatic colorectal cancer: A systematic review.
    Esin E; Yalcin S
    Cancer Treat Rev; 2016 Jan; 42():82-90. PubMed ID: 26608114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of ramucirumab for the treatment of colorectal cancer.
    Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
    Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Saridaki Z; Georgoulias V; Souglakos J
    World J Gastroenterol; 2010 Mar; 16(10):1177-87. PubMed ID: 20222160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials.
    Vogel A; Kirstein MM
    Innov Surg Sci; 2018 Jun; 3(2):85-86. PubMed ID: 31579770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.